Trial reportCancer2025
Efficacy of losartan plus modified FOLFIRINOX versus modified FOLFIRINOX in advanced pancreatic cancers: A randomized clinical trial (AFPAC Study).
Trial report in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Trial
- Targeting cancer-associated fibroblasts: therapeutic strategies, translational challenges, and future perspectives.Journal of hematology & oncology · 2026Review
- The tumor microenvironment in pancreatic cancer: from composition to therapeutic targeting.Biochemical Society transactions · 2026Review
- Review
- Review
- Pre-Emptive Amlodipine for FOLFIRINOX-Induced Hypertensive Crises Without Primary Hypertension: A Novel Chronotherapeutic Strategy.Clinical case reports · 2026Article
- The association between cardiovascular medication use and survival in patients with advanced pancreatic adenocarcinoma.Therapeutic advances in medical oncology · 2026Article
- Analysis of the SH3-Domain Kinase Binding Protein 1 Predictive Model for Pancreatic Ductal Adenocarcinoma and CCCTC-Binding Factor Transcriptional Regulatory Study.World journal of oncology · 2025Article
- Reprogramming the tumor microenvironment to overcome immunotherapy resistance in pancreatic cancer.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThe addition of angiotensin receptor blockers like losartan (L) has been shown to improve outcomes in small prospective studies of pancreatic ductal adenocarcinomas (PDAC).
methodsPatients diagnosed with treatment-naive locally advanced/metastatic PDAC with Eastern Cooperative Oncology Group performance status 0-1 and adequate end- organ function were randomly assigned (1:1) to either chemotherapy (mFOLFIRINOX or mFOLFIRINOX plus oral losartan 50 mg per day). The current unplanned analysis was conducted to identify an early signal of efficacy. Plasma TGF-β levels were measured at baseline, post cycle 1, and post cycle 4 in both arms.
resultsWith a median follow-up of 16.8 months, a total of 88 patients were randomized in the mFOLFIRINOX and mFOLFIRINOX-L arms (44 patients per arm). The number of deaths at 6 months, 6-month overall survival (OS), and median OS was 12, 72.7% (95% confidence interval [CI], 59.3-86.1), and 10.4 months versus 11, 73.2% (95% CI, 59.4-87), and 9.1 months, respectively, with a hazard ratio of 0.76 (95% CI, 0.47-1.22, p = .392). There were no differences in response rates (22% vs. 23%) between the mFOLFIRINOX and FOLFIRINOX-L arms, respectively. Nine patients (22%; n = 41) required temporary cessation of losartan due to accompanying chemotherapy-related adverse events. The trend of plasma TGF-β levels across time points was not significantly different between the two arms (ANOVA p > .05).
conclusionsThe addition of losartan to mFOLFIRINOX in the AFPAC study did not provide an early signal of efficacy in improving progression-free survival in advanced PDAC. The trial will not proceed to full accrual of phase 3 design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.